A combination of two swords: a full analysis of the mIHC+GeneScope technology protocol

In the field of immuno-oncology research and precision medicine, how to achieve deep integrated analysis from protein spatial localization to gene expression profiling has always been a major challenge for scientists. Absin innovatively launched the joint solution of GeneScope gene detection kit and multiplex fluorescence immunohistochemistry (mIHC) kit, which provides a new paradigm for tumor microenvironment research, drug efficacy prediction and clinical transformation through technical collaboration and data fusion.

Technical Collaboration: Protein-Gene Dual-Dimensional Panoramic Analysis

1. mIHC kit: high-sensitivity protein spatial localization

Absin's mIHC kit is based on Tyrosamide Signal Amplification (TSA) technology, which achieves 2-9 color multi-target colocalization of a single slide through HRP-catalyzed in-situ geometric amplification of fluorescent dyes, breaking through the monochromatic limitations of traditional immunohistochemistry. Benefits include:

- High sensitivity: Detects low-abundance targets, such as immune checkpoint proteins such as PD-1/PD-L1.

- Multicolor compatibility: By optimizing the dye combination (e.g., TSA series) and staining sequence, we can avoid spectral overlap and accurately visualize the spatial distribution of T cells, macrophages, and other subsets in the tumor microenvironment.

- Extensive sample adaptation: It supports paraffin sections, frozen sections, and organoid co-culture models, and uses antibody eluent (ABS994) to achieve multiple staining cycles and expand the research boundary.

2. GeneScope: Gene expression and function association analysis

As Absin's spatial multiomics analysis platform, GeneScope integrates transcriptome sequencing and bioinformatics tools to deeply mine gene expression networks associated with key mIHC-tagged proteins (e.g., Ki67 and CD8+ T cells). For example:

- Tumor heterogeneity analysis: Combining the protein spatial distribution of mIHC with GeneScope's gene mutation data, the molecular mechanism of tertiary lymphoid structure (TLS) and recurrence-free survival (RFS) of patients was revealed.

- Drug target prediction: Optimize the immunotherapy response prediction model through the combined analysis of PD-L1 protein expression and related signaling pathway genes (such as IFN-γ and JAK/STAT).

Application scenario: from basic research to clinical translation

- Evaluation of the efficacy of tumor immunotherapy

mIHC can simultaneously detect immune checkpoint proteins such as PD-1, CTLA-4, and FOXP3, while GeneScope further analyzes genes related to T cell exhaustion (such as TOX and TCF7), providing a multi-dimensional basis for combination drug regimens. Studies have shown that compared with traditional single-index testing, this combination technology can improve the prediction accuracy of anti-PD-1 therapy by more than 30%.

- Risk assessment of tumor recurrence

By marking cancer stem cell markers (e.g., CD133, ALDH1) by mIHC and analyzing stemness-related genes (e.g., OCT4, NANOG) by GeneScope, a recurrence risk stratification model can be constructed to guide postoperative monitoring strategies.

- Drug discovery and biomarker discovery

In CAR-T therapy or nanomedicine research, the combination technology can dynamically track immune cell infiltration (such as CD8+/CD4+ T cell ratio) and key gene expression changes before and after treatment, accelerating the screening of drug candidates.

One-stop service ecology: accurate and efficient whole-process support

Absin provides a complete ecosystem from experimental design to data mining:

- Pre-experiment optimization: Design a "strong-low-light" dye matching strategy for target abundance to avoid signal interference.

- Intelligent analysis tools: Integrate HALO, StrataQuest and other software to visualize the quantitative and spatial relationships of cell subsets.

- Open cooperation network: Establish technology-application alliances with scientific research institutes and pharmaceutical companies to promote the implementation of mIHC/GeneScope in clinical diagnostic standards.

The combination of Absin GeneScope and mIHC kits breaks down the barriers to protein and gene research, providing a panoramic view of the tumor microenvironment from "spatial localization" to "molecular mechanisms". Whether it is exploring new targets for immunotherapy or optimizing clinical diagnosis and treatment pathways, this combination of technologies will become an indispensable tool in the hands of scientists.

Contact Absin today to unlock the endless possibilities of multi-omics research!

Related Products:

https://www.absin.net/search.html?keyword=GeneScope

Absin provides antibodies, proteins, ELISA kits, cell culture, detection kits, and other research reagents. If you have any product needs, please contact us.

Absin Bioscience Inc. Email: worldwide@absin.net

Follow us on Facebook: Absin Bio